Phase II study of docetaxel in combination with oxaliplatin in patients with metastatic or locally advanced esophagogastric cancer previously untreated with chemotherapy for advanced disease: results of the Central European Cooperative Oncology Group Study ESGAS.1.2.001
Authors:
- Michael HejnaMHMichael Hejna
- Markus RadererMRMarkus Raderer
- Manuela SchmidingerMSManuela Schmidinger
- Ursula PluschnigUPUrsula Pluschnig
- Thomas BrodowiczTBThomas Brodowicz
- Christoph C. ZielinskiCZChristoph C. Zielinski
- 1 June 2008
- journal article
- case report
- Published by Wolters Kluwer Health in Anti-Cancer Drugs
- Vol. 19 (5) , 535-539
Abstract
A phase II trial was performed to determine the efficacy and tolerance of docetaxel plus oxaliplatin with hematopoietic growth factor support in previously untreated patients with advanced gastroesophageal adenocarcinoma. Thirty-five patients were entered in this trial. Treatment consisted of 3-weekly docetaxel 80 mg/m2 and oxaliplatin 100 mg/m2 both infused on day 1. A prophylactic 5-day course of human granulocyte colony-stimulating factor 5 μg/kg/day was given subcutaneously, and erythropoietin (10 000 IU subcutaneously three times per week) was administered if hemoglobin was less than 12.0 mg/dl. The confirmed overall response rate was 34%, including two complete responses (6%) and 10 partial responses (28%). Fifteen patients (43%) had stable disease. The median time to response was 2.5 months (1–3.5), the median time to progression was 8.9 (4–42.5) months and the median overall survival time was 11.6 (2.5–51) months. Hematologic toxicity was common, though World Health Organization grade 3 or 4 neutropenia occurred only in six (17%) patients and anemia in six (17%) patients, respectively. Nonhematologic adverse reactions were usually mild-to-moderate. Our data suggest that the combination of docetaxel and oxaliplatin with granulocyte colony-stimulating factor and erythropoietin has a promising therapeutic index in patients with advanced gastroesophageal adenocarcinoma.Keywords
This publication has 23 references indexed in Scilit:
- Phase III Study of Docetaxel and Cisplatin Plus Fluorouracil Compared With Cisplatin and Fluorouracil As First-Line Therapy for Advanced Gastric Cancer: A Report of the V325 Study GroupJournal of Clinical Oncology, 2006
- Chemotherapy in Advanced Gastric Cancer: A Systematic Review and Meta-Analysis Based on Aggregate DataJournal of Clinical Oncology, 2006
- A phase II study of biweekly oxaliplatin plus infusional 5-fluorouracil and folinic acid (FOLFOX-4) as first-line treatment of advanced gastric cancer patientsBritish Journal of Cancer, 2005
- Phase II Trial of Biweekly Infusional Fluorouracil, Folinic Acid, and Oxaliplatin in Patients With Advanced Gastric CancerJournal of Clinical Oncology, 2004
- Effective Combination Chemotherapy with Bimonthly Docetaxel and Cisplatin with or without Hematopoietic Growth Factor Support in Patients with Advanced Gastroesophageal CancerOncology, 2003
- The impact of hemoglobin levels on treatment outcomes in patients with cancerSeminars in Oncology, 2001
- Frontline Treatment of Advanced Gastric Cancer With Docetaxel and Granulocyte Colony-Stimulating Factor (G-CSF)American Journal of Clinical Oncology, 2000
- Phase II trial of docetaxel (Taxotere) in patients with adenocarcinoma of the upper gastrointestinal tract previously untreated with cytotoxic chemotherapy: the Eastern Cooperative Oncology Group (ECOG) Results of Protocol E1293Medical Oncology, 1996
- Evaluation of antitumour effects of docetaxel (Taxotere®) on human gastric cancers In vitro and In vivoEuropean Journal of Cancer, 1996
- Randomised comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancerBritish Journal of Cancer, 1995